HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong’s Life Health Innovations at BIO International Convention
- Written by Media Outreach
Seizing Global Business and Investment Opportunities for Sustainable Growth
HONG KONG SAR - Media OutReach Newswire - 17 June 2025 - Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) - to form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation hub.
In collaboration with InvestHK, HKSTP joined forces with the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) for the first time to form a delegation and led 16 prominent life and health technology companies to showcase at BIO 2025 held in Boston, USA.
The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms. During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities: - Immuno Cure, partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX.
- HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth.
- Allegrow Biotech Limited
- ARBELE Limited
- Beth Bioinformatics Co., Limited
- Centre for Translational Stem Cell Biology
- The Centre for Virology, Vaccinology, and Therapeutics
- DECODE CURE Limited
- GenEditBio Limited
- Great Bay Bio
- Hong Kong Universal Biologicals Company Limited
- Immuno Cure Holding (HK) Limited
- The Institute for Innovation, Translation and Policy Research (ITPR)
- LEE'S PHARMACEUTICAL (HK) LIMITED
- Serilink...

